Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: $CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Crinetics Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Crinetics Pharmaceuticals's position in the market.
Crinetics Pharmaceuticals reported strong financial results for Q1 2024, highlighted by positive data from Phase 2 studies of Atumelnant (CRN04894) in congenital adrenal hyperplasia and ACTH-dependent Cushing’s Syndrome. The company is set to present late-breaking results at ENDO in June. Additionally, a Phase 3 study for paltusotine in carcinoid syndrome is expected to start by year-end. Crinetics also secured $350 million in financing to support commercial readiness and pipeline development, totaling $901.0 million in cash and equivalents as of March 31, 2024.
Crinetics Pharmaceuticals will present advancements from their Atumelnant (CRN04894) and Paltusotine development programs at ENDO 2024. Initial data from the Phase 2 trial of Atumelnant in Congenital Adrenal Hyperplasia and findings from the Phase 1b/2a ACTH-Dependent Cushing’s Syndrome trial will be showcased. Data from Phase 3 PATHFNDR 1 and 2 trials of Paltusotine in Acromegaly, along with new long-term safety and efficacy findings, will also be presented. Crinetics aims to build the premier endocrine-focused pharmaceutical company with these developments.
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) will report its first quarter 2024 financial results on May 9, 2024. The company will host a conference call to discuss financial results and provide a business update. Investors can participate via phone or webcast.